alerted and intervene quickly if patients miss their medication. Plasma levels also decrease more slowly with long-acting injectable formulations, reducing the potential speed of a relapse occurring, which also allows earlier intervention. [5] [6] [7] Less frequent injections allows more time for patients and physicians to address other important treatment objectives such as psychosocial issues, substance abuse, smoking cessation, health maintenance, and vocational rehabilitation. 8 Paliperidone palmitate (INVEGA TRINZA ® ) is currently the only 3-monthly antipsychotic formulation approved for the treatment of schizophrenia. 9 In Phase 3 clinical trials, 3-monthly paliperidone palmitate was more effective than placebo in delaying time to relapse and reducing relapse rates. It was non-inferior to 1-monthly paliperidone palmitate in the proportion of patients that remained relapse-free. Its side-effect profile was similar to 1-monthly paliperidone palmitate and was well tolerated with no new safety concerns. 10, 11 Prior to its approval, long-acting antipsychotics were only available in 2-weekly or 4-weekly formulations. 9 
Methods
The PFP ran for 6 months and included 94 patients, enrolled by 16 prescribing clinicians in six states across Australia. All patients needed to be adequately maintained on 1-monthly paliperidone palmitate for at least 4 months prior to starting 3-monthly paliperidone palmitate. At enrolment, clinicians completed a preliminary online questionnaire for each patient supply request (Table 1) . When requesting re-supply (a second dose) they were prompted to answer additional followup questions regarding their perception of the patient's experience. A total of 23 patients (25%) received a second dose before the programme ended. At the end of the PFP, each prescriber completed a second survey on their overall experience (Table 2) .
No formal protocol was required under Medicines Australia guidance for the conduct of a PFP, as individual patient data was not collected, only aggregated data on the prescriber's experience with the product. 1
Results

Patient characteristics
Of the 94 patients enrolled, 75.5% identified as male and 24.5% female. Participants were aged from 20 to 73 years old (median 43.5 years) and age at diagnosis varied from 14 to 63 years old.
The majority of patients (77.7%) had been maintained on the higher doses of 1-monthly paliperidone palmitate, 100 mg (39.4%), and 150 mg (38.3%). The length of maintenance on 1-monthly paliperidone palmitate varied from the minimum of 4 months to 98 months (mean 28.6 ± 20.1 months); 51.1% of patients had been hospitalised due to symptom relapse in the previous 2 years prior to enrolment.
Patient experience (clinician-reported)
The most prevalent reason for prescribing 3-monthly paliperidone palmitate (94.7%) was 'convenience of 3-monthly dosing for the patient'. In 56.4% of cases the patient chose or requested 3-monthly paliperidone palmitate. In 43.6% the prescriber cited their own preference, and in 21.3% of cases prior poor medication adherence was a factor.
For the majority of patients (68.1%), clinicians reported planned follow-up care at least once-monthly and this figure remained similar (69.6%) when asked again at the re-supply stage. In 48.9% of cases, clinicians said they would consider shared care with a GP.
For all patients at the re-supply stage, clinicians reported that functioning was maintained or in 13.1% of cases functioning was improved. All patients were satisfied ('somewhat satisfied', 'very satisfied' or 'completely satisfied') with the control of their symptoms (Table 3) .
Prescriber experience
All clinicians felt confident with the administration of 3-monthly paliperidone palmitate and in identifying suitable patients for treatment. They were all either 'satisfied' (81%) or 'somewhat satisfied' (19%) with efficacy and tolerability. No one reported dissatisfaction with relapse prevention and all felt that the treatment goal for their patients was either 'met' (81.3%) or 'partly met' (18.7%) whilst on 3-monthly paliperidone palmitate. All participants reported being either 'satisfied' (62.5%) or 'somewhat satisfied' (37.5%) with the PFP itself ( Table 4) .
Discussion and conclusions
The results of these real-world experience surveys indicate a high level of satisfaction and confidence with 3-monthly paliperidone palmitate, as reported by prescribers. Collectively, prescribers felt their patients' treatment goal was met in most cases, patient functioning was maintained or improved in every case, and patients appeared satisfied with symptom control. There were no major relapses or readmissions to hospital, which would allow more opportunity to devote the time needed for psychosocial and other aspects of patient recovery.
It is anticipated that 3-monthly paliperidone palmitate will play a significant role in maintenance treatment for schizophrenia patients by delaying time to relapse and reducing non-adherence, with the potential to improve clinical outcomes and reduce the burden on the healthcare system. 7, 12 It requires less frequent dosing than other currently available antipsychotic agents, as patients only need four injections per year compared to 12 monthly injections or 24 fortnightly injections. 2 This is could benefit not only stable, high-functioning patients who are likely to find the 3-monthly dosing schedule more user-friendly but an important group who, for logistical, financial, or psychosocial reasons, struggle to access appropriate healthcare and maintain treatment. When choosing an antipsychotic, shared decision-making that considers patient preference and choice is important. 3 In other surveys from the Phase 3 clinical trials of 3-monthly paliperidone palmitate, both patients and physicians preferred long-acting injectables over oral formulations, and physicians showed a greater preference for 3-monthly versus 1-monthly dosing. 13 The findings of this Australian PFP confirmed that these were also significant factors when prescribing this medication within this setting.
A significant number of specialists indicated a willingness to share patient management with GPs. For patients who are stable and well controlled, this would reduce costs and increase convenience as the number of specialist visits 3 Given that treatment will be lifelong, it is highly likely that patients will eventually transition to their GP for ongoing care.
It is important to select the right patients for this treatment and prescribers reported that they felt confident with this. Those already adequately maintained on the 1-monthly formulation may be less likely to have previously unknown side-effect issues. There was no new or increased severity of side effects, compared to 1-monthly preparations. 10 Maintaining a regular follow-up schedule would also ensure that any adverse effects are identified and managed early. 3 Acute side effects are expected to be less of a problem where patients have already been adequately maintained on other paliperidone formulations. 14 As the enrolment period for PFPs may not exceed 6 months, the majority (75%) of patients only received one dose of 3-monthly paliperidone palmitate during the time frame allowed. 1 PFP guidelines also place limits on the data that can be collected and only aggregated patient data could be used in this study. 1 However, these data have been collected from the use of this medicine outside the constraints of randomised controlled trial conditions. Such real-world evidence is increasingly being recognised as a valuable asset in clinical decision making. 15 These findings, taken together with the available evidence base, suggest that 3-monthly paliperidone palmitate has the potential to improve adherence and clinical outcomes for schizophrenia patients.
